

## **Elekta appoints Tomas Eliasson as Vice Chair of the Board**

STOCKHOLM – Elekta (EKTAB.ST) today announced that its Board of Directors has resolved to establish the role “Vice Chair of the Board” and to appoint Tomas Eliasson to such role, effective immediately.

Tomas Eliasson has been a member of Elekta’s Board of Directors since 2023 and the Chair of its Audit Committee since 2024. He brings extensive experience from senior leadership and board roles in global industrial and technology-driven companies. His background includes deep expertise in finance, governance and strategy, supporting Elekta’s continued focus on long-term value creation.

Elekta’s Founder and Chair of the Board, Laurent Leksell, said: “Tomas is a trusted voice and contributes significantly to the Board’s work. His collaborative approach and deep experience further enhance the Board as a team. Tomas’ appointment as Vice Chair is an important step in strengthening the board when supporting Elekta’s continued value creation and profitable growth.”

Tomas Eliasson added: “I am proud to take on the role as Vice Chair of the Board of Elekta. I am also proud of the company I have been part of since 2023 and the important work Elekta does every day to improve care for patients worldwide. I look forward to supporting the Board and management as Elekta continues its development.”

# # #

### **For further information, please contact:**

Kathy Pajari, Head of Corporate Communications  
Tel: +46 76 255 6056, e-mail: [kathy.pajari@elekta.com](mailto:kathy.pajari@elekta.com)  
Time zone: CET (Central European Time)

Peter Nyquist, Head of Investor Relations  
Tel: +46 70 575 2906, e-mail: [peter.nyquist@elekta.com](mailto:peter.nyquist@elekta.com)  
Time zone: CET (Central European Time)

### **About Elekta**

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit [elekta.com](http://elekta.com).